House biomaterials liability bill inclusion in HR 10 to be proposed by Rep. Gekas.
This article was originally published in The Gray Sheet
Executive SummaryHOUSE BIOMATERIALS BILL INCLUSION IN PRODUCT LIABILITY LEGISLATION likely will be proposed by Rep. George Gekas (R-Penn.) either during committee mark-up of HR 10 or when the product liability measure reaches the House floor, according to congressional staffers. The biomaterials liability measure is thought to stand a better chance of enactment if it is included in HR 10 rather than left as a stand-alone bill, staffers say. Mark-up of HR 10 by the House Commerce Committee's Commerce, Trade and Hazardous Materials Subcommittee, chaired by Rep. Michael Oxley (R-Ohio), is scheduled to take place Feb. 21.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.